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Abstract
Background: Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75
mg/m2  and 100 mg/m2) or weekly regimens (35–40 mg/m2). The pharmacokinetics and
radiosensitizing efficacy of weekly 20 mg/m2 docetaxel, has however not been well characterized.
We examined the pharmacokinetics of weekly docetaxel when administered with concurrent
radiotherapy and compared the results with a 3-weekly 100 mg/m2 regimen.
Methods: Thirty-four patients with non small cell lung cancer (NSCLC) were included in this
study, 19 receiving 100 mg/m2 docetaxel 3-weekly as single therapy, and 15 receiving 20 mg/m2
docetaxel weekly with concurrent radiotherapy. A newly developed HPLC method was used for
measuring docetaxel levels, capable of quantifying docetaxel in plasma down to the nanomolar level.
Results: The HPLC method showed detectable concentrations of docetaxel in plasma even after
72 hours. In the present study we have demonstrated that median docetaxel plasma levels of 3 nM
can be obtained 72 hours after a dose of 20 mg/m2.
Conclusion:  The pharmacokinetics of docetaxel is characterized by great inter-individual
variability and at some time points plasma concentrations for 20 mg/m2 and 100 mg/m2 docetaxel
were overlapping. Extrapolation of these results indicates that radio sensitizing docetaxel
concentrations may be present for as long as 1 week, thus supporting the use of 20 mg/m2 weekly
docetaxel.
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Background
Docetaxel has been tested both as a single agent and in
combination with platinum as first line treatment for
NSCLC [1]. In studies with previously untreated patients
with NSCLC a dose of 100 mg/m2 every three weeks has
been used. Neutropenia occurs in most patients and dose
reduction is often required. To avoid this problem, a
weekly schedule of lower dose docetaxel has been used in
NSCLC, breast and prostate cancer. The doses of docetaxel
used were 30–40 mg/m2 either alone or in combination
with platinum. This modification of the schedule, has
been shown to be well tolerated and reduces the incidence
of severe neutropenia while maintaining therapeutic
activity [2,3].
The taxanes exert their effect by binding to the β-subunit
of tubulin promoting the polymerization of tubulin into
stable microtubules and inhibiting de-polymerization. In
addition to mitotic arrest, taxanes have been shown to
induce cell death by apoptosis both in cell cultures and in
vivo tumor system [4,5].
Studies have demonstrated that taxanes are extensively
metabolized in the liver. Clearance is affected in patients
with abnormal hepatic function but remains unaltered in
elderly patients [6]. The pharmacokinetic profile of
docetaxel is characterized by substantial inter-patient var-
iability which may have clinical implications. The area
under the plasma concentration curve (AUC) during the
first docetaxel course is a significant predictor of time to
progression [7].
Docetaxel has a high affinity for protein binding. The
binding may be as high as >95%. Only the unbound frac-
tion is clinically active. Docetaxel induced hematologic
toxicity is significantly better correlated with systemic
exposure to unbound drug than to exposure to total drug
[8]. Studies have shown that docetaxel is mainly bound to
α1-acid glycoprotein (AAG), lipoproteins and albumin.
AAG which is an acute phase protein, is often elevated
during chronic inflammation and advanced cancer. There
are great inter- individual differences in the AAG levels
which might influence the pharmacokinetics of docetaxel
and thereby its toxicity [7].
Docetaxel has also demonstrated activity as a radio sensi-
tizer in a number of preclinical and clinical studies by
blocking the cell cycle in the most radiosensitive G2/M
phase. Combination of low dose chemotherapy and tho-
racic radiotherapy has been proposed to improve the
prognosis in patients with locally advanced non-small cell
lung cancer.
Cancer cells tested in vitro gave IC50 values for docetaxel
ranging from 5 to 50 nM [9]. The radio sensitizing activity
of taxanes in vitro however is achieved even at sub-
nanomolar concentrations. Docetaxel concentrations as
low as 0.07 nM has been shown to potenziate radiother-
apy in cell lines [10]. An in vivo study in mice [11] showed
that when docetaxel was given 9 hours before radiation,
the enhancement factor was 1.45, but when radiotherapy
was delayed with 48 hours, the enhancement factor was as
high as 2.33. Docetaxel given within 2 days before irradi-
ation acts as a potent enhancer of tumor radio response
and increases the therapeutic gain of irradiation.
With concurrent radiation the weekly docetaxel doses
used ranges from 20 to 35 mg/m2. In a recent publication
[12] reviewing different phase I/II studies with concurrent
radiotherapy and docetaxel alone or in combination with
platinum compounds, a number of different doses and
schedules were used. The authors were however unable to
draw firm conclusions from the data to which dose and
schedule was the most efficient.
In our Nordic phase III combined modality study more
than 250 patients with inoperable NSCLC were rand-
omized to radiotherapy 2 Gy × 30 alone or with concur-
rent chemotherapy with docetaxel 20 mg/m2 weekly for 6
weeks. The same total dose of docetaxel was used as in our
previous phase I/II study [13] but now as 6 weekly infu-
sions rather than 4 (total dose of docetaxel 120 mg/m2),
which is the same dose as recommended by Mauer et al
[14] in their trial. The patients included in the 20 mg/m2
group were treated according to this phase III protocol.
The pharmacokinetic sampling was however not a part of
this protocol, but defined as a separate study. Several
reversed phase high performance liquid chromatographic
methods (HPLC) have been used for detecting docetaxel.
Recently a more sensitive and specific method for detect-
ing docetaxel in nanomolar concentrations in human
plasma was developed at our hospital [15].
In the present study we have used this method to monitor
pharmacokinetics of low dose docetaxel up to 72 hours.
Methods
The clinical trial was approved by the Regional Commit-
tee for Medical Research Ethics and the Hospital Review
Board. The study was in compliance with the World Med-
ical Association of Helsinki. All patients were included
after having signed a written informed consent. A separate
informed consent was obtained for patients participating
in the pharmacogenetic analyses.
The dose of docetaxel was determined by body surface
area (BSA) [16]. Docetaxel (Taxotere®  Sanofi Aventis,
Bridgewater, NJ, USA) was administered once every week
at 20 mg/m2 with concurrent radiotherapy (n = 15) or asBMC Cancer 2007, 7:197 http://www.biomedcentral.com/1471-2407/7/197
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100 mg/m2 (n = 19) as single drug every 3-weeks without
radiotherapy.
Weekly regimen (20 mg/m2)
Patient characteristics are described in Table 1.
Inclusion criteria: Histological or cytological confirmed
locally advanced NSCLC disease where surgery was not
possible. Performance status, ECOG ≤ 2. Weight loss of
less than 10% during the last 6 months. Adequate hema-
tological, pulmonary, renal and hepatic function, i.e. neu-
trophils > 1.5 × 109/l, platelets > 100 × 109/l, FEV1 > 40%,
total serum bilirubin < 1.5 × upper normal limit, serum
creatinine < 1.5 × upper normal limit, ASAT, ALAT, and
LDH ≤ 2 × upper normal limit.
3-weekly regimen (100 mg/m2)
Patient characteristics are described in Table 1.
Inclusion criteria: Histological or cytological confirmed
NSCLC with locally advanced disease not suitable for
radiotherapy with curative intention, or with metastatic
disease. The patients were physically fit for chemotherapy,
e.g. ECOG ≤ 2. Bilirubin, ASAT, ALAT < 1.5 times upper
normal limit. Predicted life expectancy ≥ 3 months.
Patient evaluation
All patients underwent a complete medical history and
physical examination, documentation of ECOG status
including routine hematology and biochemistry analysis.
Staging was done with chest radiography, computed tom-
ography of the chest and upper abdomen. Patients with
significant underlying medical conditions were excluded.
CT or MRI examination of the brain was only performed
when medically indicated.
Treatment
Weekly regimen (20 mg/m2)
Eligible patients received weekly intravenous docetaxel 20
mg/m2 for 6 courses with concurrent radiotherapy. The
chest irradiation was given to a total dose of 60 Gy (2 Gy
× 30) using a minimum of 3 treatment fields determined
by CT scan. The radiation therapy was given 5 days each
week for 6 weeks.
Docetaxel was diluted in 100 ml isotonic NaCl. Patients
were pre-treated with dexamethasone 8 mg orally twice
daily for two days, starting the day before the infusion.
Docetaxel was administered as a one hour infusion, pref-
erably on Monday or Tuesday, no later than on Wednes-
day, thus the interval between two docetaxel infusions
was 144 hours. Of 25 examined courses of docetaxel 20
mg/m2 given with concurrent radiotherapy, 21 were given
Monday or Tuesday. On the day of infusion, radiotherapy
was given within 2 hours after docetaxel infusion.
3-weekly regimen: (100 mg/m2)
The patients were treated with docetaxel for a maximum
of 6 courses. The treatment was terminated if unaccepta-
ble toxicity occurred or at disease progression. Docetaxel
was diluted in 250 ml isotonic NaCl. Pre-treatment with
dexamethasone as mentioned above. The infusion time
for docetaxel was 1 hour. The first course of chemotherapy
was given at our institution; eight patients were then
referred to their local hospital for completing the chemo-
therapy. Eleven patients received all courses of docetaxel
at our institution.
Blood sampling
Blood samples were obtained at the following time
points: pre-treatment, 30 minutes (mid-infusion), 55
minutes, 90 minutes and at 2, 3, 6, 10, 20, 25, 48 and 72
hours post infusion if possible. The samples were drawn
from an intravenous catheter located in the arm opposite
to the docetaxel infusion, collected in 9 ml tubes contain-
ing EDTA as anticoagulant (Vacuette, Greiner), and placed
on ice until additional processing within 60 minutes.
Plasma was isolated by centrifugation for 12 minutes at
1000 × g at +4°C. The plasma was frozen at -20°C after
centrifugation. For 10 of 15 patients in the weekly and 5
of 19 in the 3-weekly group, we were able to obtain blood
samples from 2 courses of chemotherapy. Two patients
treated with 100 mg/m2 were monitored for more than
two cycles. A total of 52 courses have been analyzed. Due
to practical reasons (most patients treated as out patients
etc) we were able to take blood samples at 72 hours only
Table 1: Patient characteristics
Docetaxel dose 20 mg/m2 100 mg/m2
Number of patients 15 19
Sex
Male 11 7
Female 4 12
Age, years
Median 69 63
Range 47–81 45–75
Histological type
Adenocarcinoma 3 12
Squamous cell 9 4
Large cell 1 2
Undifferentiated 2 1
Performance status
ECOG 0 6 5
ECOG 1 7 10
ECOG 2 2 4
Stage
IIIA 3
IIIB 12 4
IV 15BMC Cancer 2007, 7:197 http://www.biomedcentral.com/1471-2407/7/197
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from patients in the 20 mg/m2 group with concurrent
radiotherapy.
Analytical procedure
Plasma docetaxel concentrations were measured over the
range of 1 to 1000 nM using a validated HPLC method
developed in our laboratory. The method is described in
detail elsewhere [15]. The method has sufficient sensitiv-
ity to detect docetaxel in plasma up to 72 hours after an
infusion of 20 mg/m2 of the drug. Briefly, docetaxel was
extracted from plasma using solid phase extraction on
CN-E columns and separated on a reversed phase C-18
column. UV detection was performed at 227 nm, and
paclitaxel was used as internal standard in the assay. Sam-
ples expected to exceed the upper limit of quantitation of
the assay were prediluted in drug-free plasma according to
a defined set of volume ratios.
AAG concentrations were measured immunonephelomet-
rically on a Beckman Immage™ Immunochemistry System
(Beckman Instruments) using the Beckman AAG kit.
Pharmacokinetic calculations
Individual pharmacokinetic parameters were calculated
using PK Solutions 2.0 (Summit Research Services, CO,
USA). Area under the concentration-time curve (AUC0-t)
was determined by trapezoid calculation using measured
concentrations. Unless stated otherwise, AUCs given are
AUC0–25 h. Systemic clearance [L/h/m2] was calculated as
dose divided by AUC0–25 h.
Statistical analysis
This is a small study of a descriptive nature. A statistical
section has not been included as no statistical compari-
sons between the groups were planned in the protocol,
and no statistical comparisons between the groups were
included in the manuscript.
Results
Patient characteristics
Thirty-four patients, 18 males and 16 females with
advanced or metastatic NSCLC were enrolled in this study
between August 2000 and May 2006 (see Table 1). The
inclusion of patients in the 3-weekly part of the study was
terminated in 2002. Their median age was 63 years. The
most common histological types were adenocarcinoma
(15 patients) and squamous cell carcinoma (13 patients).
Dose administration
Fourteen patients in the weekly group received docetaxel
as planned (6 courses of docetaxel) during concurrent
radiotherapy. One patient received 3 courses of docetaxel.
We were able to administer 87/90 courses (96%) of
weekly docetaxel as planned.
Nineteen patients received docetaxel 100 mg/m2 every 3-
weeks. According to the patients files, only four patients
received the planned maximum of 6 doses of docetaxel,
median 3 courses (range 1–6).
Docetaxel pharmacokinetics
The pharmacokinetic model for docetaxel is a three-com-
partment model with first order elimination. Pharmacok-
inetic parameters for all cycles given as weekly or 3-weekly
docetaxel are shown in Table 2. Overall we had 10% miss-
ing samples due to patients receiving radiotherapy at
some time points or technical problems with blood sam-
pling. Due to missing samples, not all of the pharmacok-
inetic parameters could be calculated for all the patients.
The median docetaxel clearance for all cycles (n = 25) in
the weekly regimen was 19 (14–29) L/h/m2. Median Cmax
was 742 nM. Median AUC for the first course (n = 15) was
1360 nMh with a range from 900 to 1660. For the second
Table 2: Docetaxel pharmacokinetic parameters in patients treated with 20 mg/m2 and 100 mg/m2
All cycles*
Variables 20 mg/m2 100 mg/m2
Median Range Median Range
Cmax [nM] 742 389–1294 3737 2616–6949
AUC0–25 [nMh] 1284 848–1812 5562 3653–12790
AUC0–72 [nMh] 1541 996–2038 ND ND
Clearance [L/h/m2] 19.3 14–29 22.3 10–34
t1/2α [h] 0.99 0.8–2.0 0.74 0.5–1.0
t1/2β [ h ] 1 2 . 99 – 3 51 8 . 09 – 5 2
t1/2γ [h] 27.7 14–146 ND ND
C72h [nM] 3.0 0.7–6.5 ND ND
AAG [g/L] 1.6 0.7–2.7 1.5 0.8–2.9
*: Each variable was calculated based on 11 to 27 cycles.BMC Cancer 2007, 7:197 http://www.biomedcentral.com/1471-2407/7/197
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course (n = 10), median AUC was 1260 nMh (range 848–
1812).
The time schedule between radiotherapy and plasma con-
centration of docetaxel is illustrated in Figure 1. Docetaxel
was detectable in all samples taken at 72 hours (n = 14).
Median concentration 3.0 nM (0.7–6.5).
For all cycles (n = 27) in the 3-weekly group median
docetaxel clearance was 22 (10–34) L/h/m2. Median Cmax
was 3737 nM. The AUC range for the first course (n = 19)
of chemotherapy was 3653–12790 nMh, median 5718
nMh. For the next course (n = 5), the range was 5183–
6862 nMh and the median 5562 nMh.
The differences in intra-individual concentrations were
registered for 15 patients given two or more cycles in our
study (Table 3). When comparing AUC 2/AUC 1 for 10
patients in the 20 mg/m2 group, the median ratio was 1.12
(range 0.6–1.5). For the 3 weekly regimen, we have sam-
ples from 5 patients, the ratio of AUC 2/AUC 1 was 1.13
(range 0.9–1.5).
When analysing for AAG, the values for the weekly and
the 3-weekly groups were similar: low dose median first
course 1.7 (0.7–2.7), median second course 1.7 (0.7–2.1).
High dose: median 1.4 (0.8–2.9) for the first course and
1.5 (1.2–1.7) for the second course.
From two of the patients in the 3-weekly group we
obtained samples from three and four consecutive 3-
weekly courses. The AUCs were 4800, 5500 and 4900 for
cycle 1, 2 and 3 respectively in the first patient, the AAG
levels were, 1.3, 1.5 and 1.5 g/L.
Also in the patient that was followed for four consecutive
courses the AUCs showed minimal variation, 6600, 6000,
5800 and 6300 nMh for cycle 1, 2, 3 and 4 respectively.
Unfortunately we only obtained AAG determinations for
cycle three and four in this patient, 1.5 and 1.3 g/L.
The correlation between AUC and AAG was significant for
the 100 mg/m2 group of patients (Figure 2) but not for the
20 mg/m2 group of patients (RSQ = 0.02, p = 0.863). For
the individual patient in the 20 mg/m2 group however,
the difference in docetaxel AUC between the first and sec-
ond course correlated with the change in AAG levels
between the first and second course (Figure 3).
Toxicity
Weekly regimen: 14/15 patients completed the treatment
as planned. One patient died after 21 days due to haemo-
ptysis after receiving 3 infusions of docetaxel. The patients
were evaluated for toxicity at day 42 (end of radiotherapy)
and dysphagia/oesophagitis was recorded according to
CTC (Common Toxicity Criteria's version 2.0). Grade 2 or
higher oesophagitis occurred in 9 of the 14 (64%)
patients who fulfilled the planned treatment, and one
patient (7%) had grade 3 oesophagitis. In our small group
of patients 3 of 15 (20%) were reported with radiation
pneumonitis. The association with AUC for docetaxel and
volume of irradiated lung tissue is not clear, but all three
patients had a large volume of irradiated lung tissue.
For patients in the 3-weekly regimen, registration of toxic-
ity was mostly reported for treatment given at our institu-
tion. Except for the anticipated toxicities with fever and
infection, we observed 2 patients with serious pulmonary
toxicity. Two patients developed paraesthesia/neuropa-
thy. The reasons for discontinuation were death (2
patients), progressive disease (6 patients), and reduced
general condition (2 patients). Only 2 of 19 patients were
alive after 1 year.
Discussion
The purpose of this study was to investigate inter- and
intra-individual variability in the pharmacokinetics of
docetaxel administered as 3-weekly and weekly schedule.
Weekly docetaxel is often used in concurrent chemo-radi-
otherapy regimens. In the present study, we also exam-
ined if radio sensitizing concentrations of docetaxel in
plasma could be obtained and if the concentrations were
maintained over sufficient periods of time. Docetaxel is
eliminated mainly by the subgroup Cyp 3A4 and Cyp 3A5
of the cytochrome P 450 system [17].
Elimination curve for patients receiving 20 mg/m2 of  docetaxel Figure 1
Elimination curve for patients receiving 20 mg/m2 of 
docetaxel. Mean values (▼ ), with error bars representing 
1SD. Gray lines represent the extreme values at each time 
point. Vertical arrows labelled Rad represent the time of 
radiation treatment.
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When analyzing SNPs predictors of docetaxel clearance in
a previous study, other groups of enzymes also important
for docetaxel clearance were identified, e.g. GSTs, EPHX1/
2, BLC2, EGF and EGFR [18].
It is established that the pharmacokinetic profile of
docetaxel is characterized by substantial inter-patient var-
iability. Bruno et al [7] reported a 3.5 fold variation in
clearance in 600 patients receiving 75–100 mg/m2  of
docetaxel. Similarly, our results showed AUC values dif-
fering 3.5 fold for the 100 mg/m2 group and more than 2
Correlation between AAG and docetaxel AUC Figure 3
Correlation between AAG and docetaxel AUC. For the 20 
mg/m2 docetaxel patients that received two or more cycles, 
there was a correlation between the change in AAG-level 
and the change in docetaxel AUC0–25 between the cycles 
(RSQ = 0.63, p = 0.011).
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Table 3: Intra-individual variability in docetaxel pharmacokinetic parameters in patients treated with 20 mg/m2 and 100 mg/m2
Ratio cycle 2/cycle 1#
Variables 20 mg/m2 100 mg/m2
Median Range Median Range
Cmax 1.06 0.4–1.6 1.07 0.9–1.3
AUC0–25 1.12 0.6–1.5 1.13 0.9–1.5
AUC0–72 1.12 0.8–1.3 ND ND
Clearance 0.90 0.8–1.7 0.89 0.8–1.1
t1/2α 0.94 0.4–1.1 1.15 1.1–1.5
t1/2β 0.95 0.7–1.5 1.15 0.7–1.4
t1/2γ 1.03 0.7–1.3 ND ND
C72h 0.92 0.6–2.1 ND ND
AAG 0.98 0.7–1.7 1.15 0.9–1.4
#: Each variable was calculated based on data from 4 to 10 patients.
The relationship between AAG-level and docetaxel AUC for  patients receiving 100 mg/m2 of docetaxel (RSQ = 0.64, p <  0.0001) Figure 2
The relationship between AAG-level and docetaxel AUC for 
patients receiving 100 mg/m2 of docetaxel (RSQ = 0.64, p < 
0.0001).
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fold for the 20 mg/m2 group. Plasma concentrations for
the two groups were even overlapping at some time points
(Figure 4). Most previous pharmacokinetic data for
docetaxel originates from studies with 75–100 mg/m2
infused over 1 hour every third week. Pharmacokinetic
data for docetaxel at such high doses follow a three com-
partment model with half-lives of 4 minutes, 38 minutes
and 12 hours in the α, β and γ phase respectively up to 24
hours post infusion. Total body clearance is 21 L/h/m2,
and the volume of distribution at steady state (Vss) is 74 L/
m2 [9]. In a study by Baker et al [19] comparing pharma-
cokinetics of weekly- and 3-weekly docetaxel, it was dem-
onstrated that the docetaxel pharmacokinetics are similar
for the two dose levels. Our results are in accordance with
their findings, in our study the clearance was 22 (10–34)
L/h/m2 for the high dose patients and 19 (14–29) L/h/m2
for the low dose patients.
Few studies have reported pharmacokinetic data from
more than one course of chemotherapy for their patients.
The differences in intra-individual docetaxel concentra-
tions were registered for 15 patients. The median ratio for
AUC 2/AUC 1 was close to 1 and almost identical for the
20 mg/m2 and the 100 mg/m2 group. The range was from
0.6 to 1.5. The intra-individual differences were smaller
than the inter-individual differences, a finding which is
similar to the results in the study by Engels et al [20].
Docetaxel is to a great extent bound to plasma proteins
and we found that the intra-patient AUC 2/AUC 1 varia-
bility possibly could be explained by changes in AAG lev-
els. As described by Baker [21] serum AAG levels can vary
up to 7-fold between cancer patients, and in our study the
variation was approximately 4-fold.
We found a statistically significant correlation between
AUC and AAG for the 100 mg/m2 group of patients (Fig-
ure 2) but not for the 20 mg/m2 patients (RSQ = 0.02, p =
0.863). The difference in AUC between the first and sec-
ond course of docetaxel in the 20 mg/m2 group could
partly be explained by variations in the measured AAG
levels (Figure 3). High levels of AAG have been found to
be associated with a low fraction of "free" docetaxel which
may influence the clinical efficacy. This observed variabil-
ity in AAG levels may also complicate the interpretation of
pharmacokinetic results when based only on determina-
tions of total drug concentrations.
Bruno reported that in patients in the 100 mg/m2,
docetaxel exposure measured as AUC during the first
course of chemotherapy was the only significant predictor
of toxicity [22]. In our study 4 of the patients had AUC lev-
els above 10000. However, the patient with the highest
AUC level developed serious respiratory complications,
while for the other three no specific complications were
noted.
The use of docetaxel as a radiosensitizer was well toler-
ated, and all patients received treatment as planned except
for the patient that died from haemoptysis. The incidence
of grade 3 oesophagitis was 7% which is lower than
reported by Mauer [14] and Scagliotti [23].
The question has been raised if weekly docetaxel in 20
mg/m2 dose, used in concurrent chemo-radiotherapy reg-
imens, will give sufficient plasma levels over time to have
radio-sensitizing activity. A study by Pradier et al found
concentrations as low as 0.7 and 0.07 nM to potenziate
radiotherapy in two different cell lines [10]. Also Choy
[24], demonstrated that such low nano-molar concentra-
tions still enhance radio-sensitivity. Even in cell lines that
rarely responds to radiation or chemotherapy, docetaxel
Interpatient variations for two docetaxel dose levels Figure 4
Interpatient variations for two docetaxel dose levels. Plotting 
the total range (dotted line = median) of docetaxel concen-
trations at each time point, the graphs for the patients 
receiving 20 mg/m2 and the patients receiving 100 mg/m2 will 
overlap at some time points (e.g. at 6 h: low dose range 18–
55 nM, high dose range 51–304 nM). For simplicity, the graph 
shows determinations from 2 to 25 hours.BMC Cancer 2007, 7:197 http://www.biomedcentral.com/1471-2407/7/197
Page 8 of 9
(page number not for citation purposes)
concentrations of 0.3–1 nM was found to have a radio-
sensitizing potential [25].
There are few reports of the corresponding relationship
between plasma concentrations and the actual concentra-
tion in the tumor. In a study with paclitaxel in patients
with uterine cervical cancer, Mori et al [26] demonstrated
that paclitaxel was still retained in cancer cells for 1 week
in vivo and in vitro, thus supporting the use of weekly reg-
imens of paclitaxel.
Examining the radiobiological effects of docetaxel as a
radio sensitizer, Creane [27] found no increase in radio
sensitizing efficacy when docetaxel concentration was
raised from 4–10 nM while duration of the exposure was
more important than the actual drug concentration in the
tumor.
Baker et al [19] have demonstrated that docetaxel concen-
trations could be maintained above 1 nM for 7 days with
weekly schedules and above 0.5 nM for 21 days when
given with 3-weekly regimens. They analyzed docetaxel
concentrations for up to 21 days, and concluded that the
circulation time of docetaxel in cancer patients has been
greatly underestimated. In a study by Gustafson [28]
docetaxel concentrations after 30 mg/m2 for up to 48
hours was obtained. Extrapolating the results they found
it likely that plasma levels above 1 nM would be present
at 68 hours with this dosing. In our study, analyzing the
plasma levels at 72 hours, we could confirm that docetaxel
levels above 1 nM (median 3 nM) could be maintained as
long as 72 hours with 20 mg/m2 dose. Extrapolating our
72 hours results using a half-life of 60 hours [19], suggest
that the median docetaxel concentration was 1–2 nM
when the last radiation treatment in each weekly cycle was
given. In a recent publication by Huber [29], it could be
shown that weekly paclitaxel with concurrent radiother-
apy was superior to radiotherapy alone. Whether weekly
docetaxel with concurrent radiotherapy is also more effec-
tive than radiotherapy alone, is being addressed in the
aforementioned Nordic randomized phase III trial
recently closed for inclusion.
Conclusion
The present study demonstrates significant interpatient
differences in docetaxel pharmacokinetics. The differences
can partly be explained by differences in AAG levels, but
AAG levels may change within a week as measured in our
study. For the first time it was demonstrated that after
weekly regimen of docetaxel 20 mg/m2, docetaxel concen-
trations above 1 nM was present in plasma after 3 days.
Extrapolating the results, it can be estimated that radio-
sensitizing docetaxel levels still are maintained in plasma
after 7 days, thus providing a rationale for the use of
weekly docetaxel 20 mg/m2 and concurrent radiotherapy.
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